- ISIN
- US92337R1014
- CUSIP
- 92337R101
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 14, 2021
Highlights
- Market Cap
- $2.24B
- Enterprise Value
- $2.20B
- EPS (TTM)
- -$5.60
- EBITDA (TTM)
- -$362.33M
- Year Range
- $19.07 - $56.05
- Target Price
- $77.60
- ROA (TTM)
- -59.34%
- ROE (TTM)
- -73.84%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
VERA Performance Chart
Vera Therapeutics, Inc. (VERA) is down 38.3% since the beginning of the year. At $31 per share, VERA is trading 44.2% below its 52-week high of $56. Investors who bought $1,000 worth of VERA shares 5 years ago would now be looking at an investment worth $2,126.
Loading charts...
Returns By Period
Vera Therapeutics, Inc. (VERA) has returned -38.25% so far this year and 1.16% over the past 12 months.
Vera Therapeutics, Inc.
- 1D
- 0.03%
- 1M
- -11.94%
- YTD
- -38.25%
- 6M
- -24.21%
- 1Y
- 1.16%
- 3Y*
- 49.76%
- 5Y*
- 16.28%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
VERA Monthly Returns History
Based on dividend-adjusted daily data since May 14, 2021, VERA's average daily return is +0.25%, while the average monthly return is +5.31%. At this rate, an investment would double in approximately 1.1 years.
Historically, 44% of months were positive and 56% were negative. The best month was Jan 2024 with a return of +136.8%, while the worst month was Jan 2023 at -56.2%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 6 months.
On a daily basis, VERA closed higher 50% of trading days. The best single day was Jun 2, 2025 with a return of +67.5%, while the worst single day was Jan 4, 2023 at -64.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.57% | -5.71% | -1.37% | -11.48% | -0.25% | -11.97% | -38.25% | ||||||
| 2025 | -11.85% | -19.72% | -19.75% | -2.71% | -18.91% | 24.33% | -11.76% | 4.09% | 34.29% | -2.06% | 18.59% | 50.04% | 19.74% |
| 2024 | 136.80% | 29.27% | -8.41% | -8.37% | -3.85% | -4.76% | 1.13% | 3.36% | 16.87% | -8.64% | 23.20% | -14.99% | 174.97% |
| 2023 | -56.18% | -12.38% | 4.44% | -14.30% | 25.56% | 92.22% | 16.95% | -5.75% | -22.50% | -24.00% | 30.04% | 13.51% | -20.52% |
| 2022 | -25.41% | 16.46% | 1.21% | -14.86% | -27.30% | -6.40% | 26.75% | 25.97% | -1.93% | -12.53% | -10.41% | 15.87% | -27.58% |
| 2021 | 50.00% | -23.13% | 35.75% | -18.11% | 17.71% | 11.53% | 85.01% | -25.36% | 132.35% |
Benchmark Metrics
Vera Therapeutics, Inc. has an annualized alpha of 61.62%, beta of 1.14, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since May 17, 2021.
- This stock captured 108.19% of S&P 500 Index gains but only 68.99% of its losses - a favorable profile for investors.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 61.62%
- Beta
- 1.14
- R²
- 0.04
- Upside Capture
- 108.19%
- Downside Capture
- 68.99%
Return for Risk
Risk / Return Rank
VERA ranks 42 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Vera Therapeutics, Inc. (VERA) and compare them to S&P 500 Index.
| VERA | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.02 | 2.24 | -2.22 |
Sortino ratioReturn per unit of downside risk | 0.49 | 3.07 | -2.58 |
Omega ratioGain probability vs. loss probability | 1.06 | 1.41 | -0.34 |
Calmar ratioReturn relative to maximum drawdown | 0.03 | 2.93 | -2.90 |
Martin ratioReturn relative to average drawdown | 0.05 | 13.52 | -13.47 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Vera Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Vera Therapeutics, Inc. was 84.89%, occurring on Jan 9, 2023. Recovery took 266 trading sessions.
The current Vera Therapeutics, Inc. drawdown is 43.83%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -84.89%Jan 2023 | 1y 1mo | 1y 22d | 2y 2moDec 2021 - Jan 2024 |
2025 selloff2025 | -62.09%Apr 2025 | 4mo 7d | 8mo 8d | 1y 10dDec 2024 - Dec 2025 |
2021 bear market2021 | -50.95%Oct 2021 | 29d | 1mo 5d | 2mo 4dSep 2021 - Nov 2021 |
2026 bear market2026 | -43.85%Jun 2026 | 5mo 8d | — | 5mo 10dDec 2025 - now |
2021 bear market2021 | -33.60%Jun 2021 | 1mo 6d | 2mo 5d | 3mo 11dMay 2021 - Sep 2021 |
Drawdown Indicators
| VERA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -84.89% | -56.78% | -28.11% |
Max Drawdown (1Y)Largest decline over 1 year | -43.85% | -9.10% | -34.75% |
Max Drawdown (3Y)Largest decline over 3 years | -62.09% | -18.90% | -43.19% |
Max Drawdown (5Y)Largest decline over 5 years | -84.89% | -25.43% | -59.46% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -43.83% | -0.74% | -43.09% |
Average DrawdownAverage peak-to-trough decline | -40.02% | -10.72% | -29.30% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 24.61% | 1.97% | +22.64% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Vera Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Vera Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for VERA in comparison with other companies in the Biotechnology industry. Currently, VERA has a P/B value of 4.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with VERA
Add Vera Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with VERA